

## Increasing incidence of Gram-negative organisms in bacterial agents isolated from diabetic foot ulcers

Vedat Turhan<sup>1\*</sup>, Mesut Mutluoglu<sup>2\*</sup>, Ali Acar<sup>1</sup>, Mustafa Hatipoğlu<sup>1</sup>, Yalçın Önem<sup>3</sup>, Gunalp Uzun<sup>2</sup>, Hakan Ay<sup>2</sup>, Oral Öncül<sup>1</sup>, Levent Görenek<sup>1</sup>

<sup>1</sup> Gata Haydarpaşa Training Hospital, Department Of Infectious Diseases And Clinical Microbiology, Istanbul, Turkey

<sup>2</sup> Gata Haydarpaşa Training Hospital, Department of Underwater and Hyperbaric Medicine, Istanbul, Turkey

<sup>3</sup> Gata Haydarpaşa Training Hospital, Department of Internal Medicine, Istanbul, Turkey

\*Vedat Turhan and Mesut Mutluoglu have contributed equally to this manuscript and hold equal authorship

### Abstract

**Introduction:** In the present study, we sought to identify the bacterial organisms associated with diabetic foot infections (DFIs) and their antibiotic sensitivity profiles.

**Methodology:** We retrospectively reviewed the records of wound cultures collected from diabetic patients with foot infections between May 2005 and July 2010.

**Results:** We identified a total of 298 culture specimens (165 [55%] wound swab, 108 [36%] tissue samples, and 25 [9%] bone samples) from 107 patients (74 [69%] males and 33 [31%] females, mean age 62 ± 13 yr) with a DFI. Among all cultures 83.5% (223/267) were monomicrobial and 16.4% (44/267) were polymicrobial. Gram-negative bacterial isolates (n = 191; 61.3%) significantly outnumbered Gram-positive isolates (n = 121; 38.7%). The most frequently isolated bacteria were *Pseudomonas* species (29.8%), *Staphylococcus aureus* (16.7%), *Enterococcus* species (11.5%), *Escherichia coli* (7.1%), and *Enterobacter* species (7.1%), respectively. While 13.2% of the Gram-negative isolates were inducible beta-lactamase positive, 44.2% of *Staphylococcus aureus* isolates were methicillin resistant.

**Conclusions:** Our results support the recent view that Gram-negative organisms, depending on the geographical location, may predominate in DFIs.

**Key words:** diabetic foot infection; bacterial pathogens; culture; Gram-positive bacteria; Gram-negative bacteria

*J Infect Dev Ctries* 2013; 7(10):707-712. doi:10.3855/jidc.2967

(Received 30 August 2013 – Accepted 28 January 2013)

Copyright © 2013 Turhan *et al.* This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Introduction

Diabetes, with its increasing prevalence and incidence, is regarded as a global health problem. Today, it affects approximately 171 million people worldwide and this number is estimated to reach 366 million in 2030 [1]. In Turkey, 7.2 % of the population has diabetes [2]. Diabetic foot infections (DFIs) are associated with significant mortality and morbidity and are the leading cause of non-traumatic lower extremity amputations [3-5].

Because the results of wound cultures are available in one to three days on average, comprehensive empirical antimicrobial therapy covering the most probable causative agents is a key factor in the management of DFIs. Moreover, given the fact that many patients receive antimicrobial treatment prior to wound sampling, some cultures may yield false

negative results and clinicians may have to rely solely on their clinical consideration.

Microbiological studies of DFIs conducted so far have yielded inconsistent results. This discrepancy might be attributed to the varying methodological design and quality among studies. The prevailing belief that *Staphylococcus aureus* is the predominant pathogen in DFIs has been derived mainly from studies undertaken in Western countries [5,6]. Recent studies from Eastern countries, however, have raised skepticism about this assumption [7-10]. Turkey is a transition point between the Eastern and Western countries. In the current study, we sought to demonstrate the microbiological profile and antibiotic susceptibility patterns of organisms isolated from diabetic patients in a tertiary hospital in Turkey.

**Table 1.** The distribution of bacteria isolated from diabetic foot infections

Bacteria	N	% <sup>a</sup>	% <sup>b</sup>
Gram-positive bacteria			
<i>Staphylococcus aureus</i> (MS) <sup>c</sup>	29	9.3	24.2
<i>Staphylococcus aureus</i> (MR) <sup>c</sup>	23	7.4	19.2
<i>Enterococcus</i> spp	36	11.5	30.0
<i>Staphylococcus</i> (coagulase negative)	16	5.1	13.3
<i>Micrococcus</i> spp	9	2.9	6.7
<i>Streptococcus</i> spp	8	2.6	6.7
Total	121	38.7	100
Gram negative bacteria			
<i>Pseudomonas</i> spp	93	29.8	48.7
<i>Enterobacter</i> spp	22	7.1	11.5
<i>Escherichia coli</i>	22	7.1	11.5
<i>Klebsiella</i> spp	12	3.8	6.3
<i>Proteus</i> spp	15	4.8	7.9
<i>Acinetobacter</i> spp	8	2.6	4.2
Other Gram negatives <sup>d</sup>	19	6.1	9.9
Total	191	61.3	100

<sup>a</sup> Rate within all isolates<sup>b</sup> Rate depending on Gram staining<sup>c</sup> MS, methicillin-sensitive; MR, Methicillin-resistant<sup>d</sup> *Citrobacter* spp., *Serratia* spp, *Stenotrophomonas* spp, *Burkholderia* spp, *Morganella morganii*, *Pantoea agglomerans*, *Edwardsiella tarda*, *Providencia rustigianii* (0-1.4%)

## Methodology

The records of diabetic patients with foot infections admitted to the Underwater and Hyperbaric Medicine Center between May 2005 and July 2010 were reviewed and those with a wound culture, assessed by the Infectious Diseases and Clinical Microbiology (IDCM) Laboratory, were enrolled in the study. Wound cultures from both inpatients and outpatients were included. Both centers are affiliated with Gulhane Military Medical Academy Haydarpaşa Teaching Hospital, which is a referral center for diabetic patients with foot infections in Istanbul, Turkey.

We obtained a wound culture from a diabetic patient if he/she had clinical signs of wound infection on the day of admittance; cultures were repeated when clinically indicated. Wound culture results were presented in Table 1. The Ethical Committee of Gulhane Military Medical Academy Haydarpaşa Teaching Hospital approved the study protocol (#2012-26).

Swab samples were obtained using sterile swabs, following the removal of debris-containing tissues and

cleansing the wound and peri-wound with sterile normal saline. Deep tissue samples were obtained from the viable and non-viable tissue junction using a curette or punch biopsy material. We obtained bone specimens during surgical debridement using a rongeur whenever possible.

The IDCM laboratory performed microorganism identification and antibiotic sensitivity testing. The specimens were incubated at 37°C for 24 to 48 hours on eosin methylene blue, chocolate and 5% sheep blood agars. Microorganisms were identified by standard methods based on the morphology of the colonies, microscopic appearance of bacteria, Gram-staining, and by using rapid Gram-positive and -negative identification kits (BBL Crystal Identification System, Becton Dickinson Co, Cockeysville, Md., USA). Anaerobic culturing was not routinely performed in the IDCM laboratory.

Antibiotic sensitivity testing was performed by the Kirby-Bauer disc diffusion method and interpreted in accordance with Clinical and Laboratory Standards Institute (CLSI, 2005) guidelines [11]. The procedure involved swabbing of 0.5 McFarland testing

**Table 2.** Percentage of in vitro susceptibility of Gram-positive aerobic organisms to antimicrobials (%)<sup>a</sup>

Bacteria	CIP	SAM	SXT	VA	MET	LNZ	FA	TE	P	E	LEV
<i>Staphylococcus aureus</i> (MS)	71	100	50	100	100	100	100	72	48	71	95
<i>Staphylococcus aureus</i> (MR)	35	50	56	100	0	90	100	55	13	34	0
<i>Enterococcus</i> spp.	30	90	26	97	9	93	61	11	79	19	60
<i>Staphylococcus</i> (coagulase negative)	28	50	61	100	12	93	100	28	20	25	57
<i>Micrococcus</i> spp.	33	20	60	100	50	100	80	50	37	25	0
<i>Streptococcus</i> spp.	50	40	40	100	16	83	60	0	25	50	100

<sup>a</sup> CIP, ciprofloxacin; SAM, Ampicillin/sulbactam; SXT, trimethoprim-sulfamethoxazole; VA, vancomycin; MET, methicillin, LNZ, linezolid, FA, fusidic acid, TE, tetracycline, P, penicillin; E, erythromycin, LEV, levofloxacin.

microorganism over ceftazidime (30 µg) and ceftazidime/clavulanic acid (30/10 µg) discs, placed on a Mueller Hinton agar plate. Any microorganism (*Klebsiella pneumoniae*, *K. oxytoca*, *Escherichia coli* and *Proteus mirabilis*) was considered as extended spectrum beta-lactamases (ESBL) positive if there was an increase  $\geq 5$  mm in zone diameter with ceftazidime/clavulanate versus its zone size when tested with only ceftazidime disc. Inducible beta-lactamases (IBL) positive microorganisms were identified using the double disc method according to Sanders and Sanders [12]. Cefoxitin was used as inducer of these beta-lactamases. The induction of beta-lactamase was indicated by the occurrence of antagonism between the cefoxitin disc and the antibiotic being tested. Methicillin resistance was tested by using the cefoxitin disc diffusion method (30 µg). An inhibition zone diameter of  $\leq 21$  mm for *S. aureus* and  $\leq 24$  mm for coagulase-negative *Staphylococcus* was reported as methicillin resistant.

## Results

A total of 298 wound cultures from 107 patients with diabetic foot ulcers were identified. There were 74 (69%) male and 33 (31%) female patients. The mean age of the patients was  $62 \pm 13$  years (range: 18 to 95 years), and the mean HbA1c was  $9 \pm 2.5$  % (range: 4.8% to 16.4 %).

Of the 298 samples, 165 (55%) were wound swabs, 108 (36%) were deep tissue samples, and 25 (9%) were bone specimens. Thirty-one samples did not show any bacterial growth. Among 267 culture-positive samples, a total of 312 aerobic bacteria were identified. Polymicrobial isolates were detected in 44 (16%) samples. The average number of isolates per culture-positive sample was 1.16.

The distribution of isolated bacteria is shown in Table 1. There were 121 (38.7%) Gram-positive isolates and 191 (61.3%) Gram-negative isolates. Among all isolates, *Pseudomonas* spp. was the most frequent bacteria (n = 93; 29.8%), followed by *S. aureus* (n = 52; 16.7%) and *Enterococcus* spp (n = 36; 11.5%).

Among Gram-positive isolates, *S. aureus* was the most frequently isolated species (43.4%). Of these, 44.2% were methicillin-resistant *S. aureus* (MRSA). The second most frequent Gram-positive organism was *Enterococcus* spp. (n = 36; 30%). Coagulase-negative *Staphylococci*, which are usually recognized as colonizers, were isolated in 16 (13.3%) wound cultures.

*Pseudomonas* species were the most frequently isolated bacteria among Gram-negatives (48.7%) followed by *Enterobacter* spp (11.5%) and *Escherichia coli* (11.5%). While 30 (32.2%) of the *P. aeruginosa* and 15 (17.6%) of the *Enterobacteriaceae* species demonstrated IBL activity, two *Escherichia coli* and one *Klebsiella oxytoca* species expressed ESBL activity.

*In-vitro* sensitivities of isolated bacteria are illustrated in Tables 2 and 3. While one of the *E. faecalis* species demonstrated vancomycin resistance (VREF), the remaining Gram-positive species were sensitive to vancomycin. Fusidic acid was efficient against all *Staphylococcus* species including those with methicillin resistance. Most of the Gram-negative isolates were sensitive against sulbactam/cefoperazone and tazobactam/piperacillin. Most isolates were also sensitive against ceftadizime, amikacin and imipenem. Two (25%) of the *Acinetobacter* spp isolates had imipenem resistance

**Table 3.** Percentage of in vitro susceptibility of Gram-negative aerobic organisms to antimicrobials (%)<sup>a</sup>

Bacteria	AK	CIP	CTX	CAZ	AMC	SXT	TPZ	IPM	CES	ATM
<i>Pseudomonas</i> spp.	68	40	12	63	5	19	93	50	73	56
<i>Enterobacter</i> spp.	86	77	71	76	9	68	100	76	100	62
<i>Escherichia coli</i>	85	45	59	81	31	33	100	100	100	78
<i>Klebsiella</i> spp.	81	27	58	75	41	27	100	83	100	63
<i>Proteus</i> spp.	92	86	93	93	66	66	100	100	100	91
<i>Acinetobacter</i> spp.	57	16	0	37	0	25	12	71	50	75
Other Gram-negatives <sup>b</sup>	64	40	64	88	47	37	75	94	100	64

<sup>a</sup>AK, amikacin, CIP, ciprofloxacin; CTX, cefotaxime, CAZ, ceftazidime; AMC, amoxicillin / clavulanic acid, SXT, trimethoprim / sulphamethoxazol; TPZ, tazobactam / piperacillin, IPM, imipenem, CES, sulbactam / cefoperazone, ATM, aztreonam

<sup>b</sup> *Citrobacter* spp., *Serratia* spp., *Stenotrophomonas* spp., *Burkholderia* spp., *Morganella morganii*, *Pantoea agglomerans*, *Edwardsiella tarda*, *Providencia rustigianii* (0-1.4%).

## Discussion

Since the early 1980s, DFIs are recognized to be polymicrobial in nature. Gram-positive cocci are almost always the most commonly isolated organisms, followed by Gram-negative and anaerobic bacteria. The majority of the studies conducted during the last two decades in Western countries have shown that unless antibiotics have been used prior, cultures from acute diabetic foot wounds grow a single pathogen, which is usually *S. aureus* or *Streptococcus* spp [13].

In the current study, 312 bacteria were isolated from 267 specimens, with a rate of 1.16 isolates per culture (IPC). While these results compare favorably with several previous studies such as those by Hayat *et al.* (1.24 IPC) [14] and Viswanathan *et al.* (1.21 IPC) [15], they differ from several others, such as the investigation by Citron *et al.* [6], which revealed 2.7 IPC among aerobic and 2.3 IPC among anaerobic bacteria in a diabetic population involving 433 patients with foot infections.

Our finding that 61.3% of the overall isolates were Gram-negative aerobic agents is of note. Several studies from the recent literature have reported similar observations. Gadapelli *et al.* [7], Shankar *et al.* [8], Ramakant *et al.* [9] and Raja [10], from Eastern developing countries and Şerefhanoglu *et al.* [16] and Örmen *et al.* [17] from Turkey, reported an increase in the prevalence of aerobic Gram-negative bacteria isolated from DFIs.

Another interesting and important observation of this study was the apparent predominance of *Pseudomonas* species, particularly among Gram-negative isolates (48.7%) but also among all isolates (29, 8%). This observation may be attributed in part to the chronic and/or recurrent characteristics of wound infections in our patient population. Several studies

with large patient cohorts, especially those from Pakistan and India, have reported similar rates of *Pseudomonas* in diabetic patients with foot infections [7,8]. While Abdulrazak *et al.* [18] reported a 17.5% rate of *P. aeruginosa* among all isolates, Ramakant *et al.* [9] and Hayat *et al.* [14] reported rates of 27.05% and 20.1%, respectively. The majority of these studies have also reported a proportional increase in the prevalence of multi-drug resistance among pathogens identified from DFIs during the same period. In the current study, carbapenem sensitivity was 49.4% and multidrug resistant strains represented almost one third of all *Pseudomonas* species. Shankar *et al.* [8] from South India and Kandemir *et al.* [19] from Turkey reported 44% and 45% rates for multidrug resistant *P. aeruginosa* strains isolated from patients with DFIs, respectively. Kandemir *et al.* [19] demonstrated that risk factors such as the duration of past antibiotic use, prolonged hospitalization, and the presence of neuro-ischemic diabetic foot ulcers and osteomyelitis were closely associated with multiple drug resistance.

In a multi-center study (“SIDESTEP”) conducted by Lipsky *et al.* [20], ertapenem, which is known to be ineffective against *Pseudomonas* species, was compared with piperacilin/tazobactam in diabetic patients with foot infections. Although some wound cultures involved *P. aeruginosa*, piperacilin/tazobactam and ertapenem protocols surprisingly revealed similar outcomes. The authors from this study, as well as several others from western countries, have pointed out that *P. aeruginosa* was a commensal organism rather than a causative pathogen and hence would not require any specific antimicrobial coverage. According to Lipsky *et al.*, wound care measures such as avoiding moisture in the peri-wound environment, frequent changing of wound dressings,

and avoiding hydrotherapy-based wound care modalities would be sufficient to eradicate *P. aeruginosa*.

*S. aureus* has long been recognized as the predominant pathogen in DFIs. In the current study, however, it was the second most frequently isolated agent, coming after *P. aeruginosa*. Following the 1990s, community-acquired MRSA emerged as an important pathogen in DFIs, comprising between 12% to 40% of all *Staphylococcus* species [16]. We found a high rate (44.2%) of methicillin resistance in our series. Nevertheless, in a recent review, Lima *et al.* [21] reported an increase in antibiotic resistance among diabetic patients with foot infections and recommended the avoidance of wide empirical antibiotic coverage unnecessarily. Another important finding of this study was the fact that fusidic acid was efficient against all *S. aureus* species, including MRSA. Fusidic acid may be considered an important therapeutic alternative, particularly in mild to moderate DFIs.

In a recent study performed on diabetic patients with foot infections [22], while Gram-negative agents represented 38% of all organisms isolated from superficial wound cultures, they comprised almost twice the rate (67%) in patients with diabetic foot osteomyelitis. This finding suggests that the more chronic or complicated (*e.g.*, presence of osteomyelitis) DFIs are, the more Gram-negative agents will predominate [23].

Our study has several limitations. Because our hospital is a referral center for patients with DFIs, the majority of our patients had received several courses of antimicrobial treatment previously. However, due to missing data, we were not able to compare the relationship between antibiotic usage and culture results. Additionally, the current study is limited by the lack of anaerobic sampling. As humans live longer, the steady increase in diabetes and its associated complications such as DFIs will translate into a rising health-care burden worldwide. The traditional recognition that “DFIs are mostly caused by *S. aureus* or Gram-positive species” may not reflect a universal clinical feature, and geographic variances emphasize the need for local treatment guidelines [24]. This necessity has lately been demonstrated by many studies, including the current one, and those from Eastern countries, which reported a significant shift toward more Gram-negative organisms isolated from DFIs. Comprehensive empirical antimicrobial coverage is a key factor for successful DFI management; hence we need more, larger, prospective

and controlled studies from all over the world to better address this issue.

## References

1. Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care* 27: 1047-1053.
2. Satman I, Yilmaz T, Sengül A, Salman S, Salman F, Uygur S, Bastar I, Tütüncü Y, Sargin M, Dinççag N, Karsidag K, Kalaça S, Ozcan C, King H (2002) Population-based study of diabetes and risk characteristics in Turkey: results of the Turkish Diabetes Epidemiology Study (TURDEP). *Diabetes Care* 25: 1551-1556.
3. Mancini L, Ruotolo V (1997) Diabetic foot: epidemiology. *Rays* 22: 511-523.
4. Lavery LA, Armstrong DG, Wunderlich RP, Tredwell J, Boulton AJ (2003) Diabetic foot syndrome: evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. *Diabetes Care* 26: 1435-1438.
5. Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, LeFrock JL, Lew DP, Mader JT, Norden C, Tan JS; Infectious Diseases Society of America. (2004) Diagnosis and treatment of diabetic foot infections. *Clin Infect Dis* 39: 885-910.
6. Citron DM, Goldstein EJ, Merriam CV, Lipsky BA, Abramson MA (2007) Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. *J Clin Microbiol* 45: 2819-2828.
7. Gadepalli R, Dhawan B, Sreenivas V, Kapil A, Amini AC, Chaudhry RA (2006) Clinico-microbiological study of diabetic foot ulcers in an Indian Tertiary Care Hospital. *Diabetes Care* 29:1727-1732.
8. Shankar EM, Mohan V, Premalatha G, Srinivasan RS, Usha AR (2005) Bacterial etiology of diabetic foot infections in South India. *Eur J Intern Med* 16: 567-570.
9. Ramakant P, Verma AK, Misra R, Prasad KN, Chand G, Mishra A, Agarwal G, Agarwal A, Mishra SK (2011) Changing microbiological profile of pathogenic bacteria in diabetic foot infections: time for a rethink on which empirical therapy to choose? *Diabetologia* 54: 58-64.
10. Raja NS (2007) Microbiology of diabetic foot infections in a teaching hospital in Malaysia: a retrospective study of 194 cases. *J Microbiol Immunol Infect* 40: 39-44
11. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. Document M100-S15, Wayne PA: CLSI, 2005.
12. Sanders CC., and Sanders, WE (ID) (1979). Emergence of resistance to cefamandole: possible role of ceftoxitin-inducible beta-lactamases. *Antimicrob. Agents Chemother.* 15: 792-797.
13. Kosinski MA, Lipsky BA (2010) Current Medical Management of Diabetic Foot Infections. *Expert Rev Anti Infect Ther* 8: 1293-1305.
14. Hayat SA, Khan HA, Masood N and Shaikh N (2011) Study for Microbiological Pattern and In vitro Antibiotic Susceptibility in Patients Having Diabetic Foot Infections at Tertiary Care Hospital in Abbottabad. *World Applied Sciences Journal* 12: 123-131.
15. Viswanathan V, Jasmine JJ, Snehalatha C, Ramchandran A (2002) Prevalence of pathogens in diabetic foot infection in South Indian type 2 diabetic patients. *J Assoc Physicians India* 50: 1013-1016.

16. Şerefhanoglu K, Turan H, Ergin TF, Arslan H (2006) Aerobic Bacteriological Analysis of Diabetic Foot Infections. *ANKEM Derg* 20: 85-88.
17. Örmen B, Türker N, Vardar I, Coskun NA, Kaptan F, Ural S, El S, Turker M (2007) Clinical and bacteriological analysis of diabetic foot infections. *İnfek Derg (Turkish Journal of Infection)* 21: 65-69.
18. Abdulrazak A, Bitar ZI, Al-Shamali AA, Mobasher LA (2005) Bacteriological study of diabetic foot infections. *J Diabetes Complications* 19: 138-141.
19. Kandemir O, Akbay E, Sahin E, Milcan A, Gen R (2007) Risk factors for infection of the diabetic foot with multi-antibiotic resistant microorganisms. *J Infect* 54: 439-445.
20. Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA (2005) Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. *Lancet* 366: 1695-1703.
21. Lima AF, Costa LB, Silva JL, Maia MBS, Ximenes ECPA (2011) Interventions for wound healing among diabetic patients infected with *Staphylococcus aureus*: a systematic review. *Sao Paulo Med J* 129: 165-170.
22. Bozkurt F, Gülsün S, Tekin R, Hoşoğlu S, Acemoğlu H (2011) Comparison of microbiological results of deep tissue biopsy and superficial swab in diabetic foot infections. *J Microbiol Infect Dis* 1: 122-127.
23. Turhan V, Önem Y, Mutluoğlu M, Uzun G, Ay H (2012) Comments on “Comparison of microbiological results of deep tissue biopsy and superficial swab in diabetic foot infections”. *J Microbiol Infect Dis* 2: 76-77.
24. Tiwari S, Pratyush DD, Dwivedi A, Gupta SK, Rai M, Singh SK (2012) Microbiological and clinical characteristics of diabetic foot infections in northern India. *J Infect Dev Ctries* 6: 329-332.

### Corresponding author

Vedat Turhan

Assoc.Prof of Infectious Diseases and Clinical Microbiology,

GATA Haydarpaşa T. Hospital, Tıbbiye Caddesi,

Selimiye Mahallesi, Uskudar, Istanbul

Tel: +90-532-2059671

Fax: +90-216-3487880

Email: vedatturhan@yahoo.com

**Conflict of interests:** No conflict of interests is declared.